Agmatine attenuates nicotine induced conditioned place preference in mice through modulation of neuropeptide Y system

Behavioural Brain Research

Volumn 262, Issue , 2014, Pages 118-124

  Kotagale, Nandkishor R ^a   Walke, Sonali ^a   Shelkar, Gajanan P ^b   Kokare, Dadasaheb M ^b   Umekar, Milind J ^a   Taksande, Brijesh G ^a  

^a New Kamptee   (India)

^b RTM NAGPUR UNIVERSITY   (India)

Author keywords

Agmatine; CPP; Neuropeptide Y; Nicotine

Indexed keywords

AGMATINE; CPP; NEUROPEPTIDE Y; NICOTINE;

AGMATINE; ANIMALS; BRAIN; CONDITIONING (PSYCHOLOGY); DRUG INTERACTIONS; MALE; MICE; MOTOR ACTIVITY; NEUROPEPTIDE Y; NICOTINE; NICOTINIC AGONISTS;

EID: 84893445602     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.01.004     Document Type: Article

References (47)

1. Aricioglu-Kartal F., Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci 1997, 61:1775-1781.
2. Bhisikar S.M., Kokare D.M., Nakhate K.T., Chopde C.T., Subhedar N.K. Tolerance to ethanol sedation and withdrawal hyper-excitability is mediated via neuropeptide Y Y1 and Y5 receptors. Life Sci 2009, 85(21-22):765-772.
3. Biala G. Calcium channel antagonists suppress nicotine induced place preferences and locomotor sensitization in rodents. Pol J Pharmacol 2003, 55:327-335.
4. Biala G., Budzynska B., Staniak N. Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Behav Brain Res 2009, 202:260-265.
5. Brielmaier J.M., McDonald C.G., Smith R.F. Nicotine place preference in a biased conditioned place preference design. Pharmacol Biochem Behav 2008, 89:94-100.
6. Britton K.T., Akwa Y., Spina M.G., Koob G.F. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 2000, 21(1):37-44.
7. Brown C.M., Coscina D.V., Fletcher P.J. The rewarding properties of neuropeptide Y in perifornical hypothalamus vs nucleus accumbens. Peptides 2000, 21:1279-1287.
8. Chen H., Hansen M.J., Jones J.E., Vlahos R., Bozinovski S., Anderson G.P., et al. Regulation of hypothalamic NPY by diet and smoking. Peptides 2007, 28:384-389.
9. Deo G.S., Dandekar M.P., Upadhya M.A., Kokare D.M., Subhedar N.K., Neuropeptide Y Y1 receptors in the central nucleus of amygdala mediate the anxiolytic-like effect of allopregnanolone in mice: behavioral and immunocytochemical evidences. Brain Res 2010, 1318:77-86.
10. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000, 393:295-314.
11. de Quidt M.E., Emson P.C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system-II. Immunohistochemical analysis. Neuroscience 1986, 18:545-618.
12. Goyal S.N., Kokare D.M., Chopde C.T., Subhedar N.K. Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats. Pharmacol Biochem Behav 2006, 85(2):369-377.
13. Halaris A., Plietz J. Agmatine metabolic pathway and spectrum of activity in brain. CNS Drugs 2007, 21:885-900.
14. Itasaka M., Hanasawa M., Hironaka N., Miyata H., Nakayama K. Facilitation of intracranial self-stimulation behavior in rats by environmental stimuli associated with nicotine. Physiol Behav 2012, 107:277-282.
15. Jiménez-Vasquez P.A., Mathé A.A., Thomas J.D., Riley E.P., Ehlers C.L. Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Dev Brain Res 2001, 131(1-2):149-152.
16. Josselyn S.A., Beninger R.J. Neuropeptide Y: intraaccumbens injections produce a place preference that is blocked by cis-flupenthixol. Pharmacol Biochem Behav 1993, 46:543-552.
17. Kask A., Rägo L., Harro J. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. Br J Pharmacol 1998, 124(7):1507-1515.
18. Kask A., Kivastik T., Rägo L., Harro J. Neuropeptide Y Y1 receptor antagonist BIBP3226 produces conditioned place aversion in rats. Prog Neuropsychopharmacol Biol Psychiatry 1999, (23):705-711.
19. Kokare D.M., Shelkar G.P., Borkar C.D., Nakhate K.T., Subhedar N.K. A simple and inexpensive method to fabricate a cannula system for intracranial injections in rats and mice. J Pharmacol Toxicol Methods 2011, 64(3):246-250.
20. 2-adrenoceptors. Behav Brain Res 2010, 213:161-174.
21. Kotagale N.R., Paliwal N.P., Aglawe M.M., Umekar M.J., Taksande B.G. Possible involvement of neuropeptide Y Y1 receptors in antidepressant like effect of agmatine in rats. Peptides 2013, 47:7-11.
22. Laviolette S.R., van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 2004, 5:55-65.
23. Li M.D., Kane J.K., Parker S.L., McAllen K., Matta S.G., Sharp B.M. Nicotine administration enhances NPY expression in the rat hypothalamus. Brain Res 2000, 867:157-164.
24. Meurs A., Clinckers R., Ebinger G., Michotte Y., Smolders I. Clinical potential of neuropeptide Y receptor ligands in the treatment of epilepsy. Curr Top Med Chem 2007, 7(17):1660-1674.
25. Morgan A.D., Campbell U.C., Fons R.D., Carroll M.E. Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats. Pharmacol Biochem Behav 2002, 72:873-880.
26. Mormède P., Castagné V., Rivet J.M., Gaillard R., Corder R. Involvement of neuropeptide Y in neuroendocrine stress responses. Central and peripheral studies. J Neural Transm Suppl 1990, 29:65-75.
27. Nakhate K.T., Dandekar M.P., Kokare D.M., Subhedar N.K. Involvement of neuropeptide Y Y(1) receptors in the acute, chronic and withdrawal effects of nicotine on feeding and body weight in rats. Eur J Pharmacol 2009, 609:78-87.
28. Paxinos G., Franklin R.B.J. The mouse brain in stereotaxic coordinates 1997, Academic Press, San Diego.
29. Prasad A., Prasad C. Agmatine enhances caloric intake and dietary carbohydrate preference in satiated rats. Physiol Behav 1996, 60(4):1187-1189.
30. Quarta D., Leslie C.P., Carletti R., Valerio E., Caberlotto L. Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology 2011, 60:328-335.
31. Reis D.J., Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 1998, 72(2-3):80-85.
32. Reis D.J., Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol Sci 2000, 21:187-193.
33. Rylkova D., Boissoneault J., Isaac S., Prado M., Shah H.P., Bruijnzeel A.W. Effects of NPY and the specific Y1 receptor agonist [d-His]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. Neuropeptides 2008, 42:215-227.
34. Sahrarei H., Fahali M., Zarrindast M., Sabetkaseai M., Ghoshooni H., Khalili M. The effects of nitric oxide on the acquisition and expression of nicotine-induced conditioned place preference in mice. Eur J Pharmacol 2004, 503:81-87.
35. Schroeder J.P., Olive F., Koenig H., Hodge C.W. Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration. Alcohol Clin Exp Res 2003, 27:1884-1891.
36. Sørensen G., Wegener G., Hasselstrøm J., Hansen T.V., Wörtwein G., Fink-Jensen A., et al. Neuropeptide Y infusion into the shell region of the rat nucleus accumbens increases extracellular levels of dopamine. Neuroreport 2009, (20):1023-1026.
37. Su R.B., Wang W.P., Lu X.Q., Wu N., Liu Z.M., Li J. Agmatine blocks acquisition and re-acquisition of intravenous morphine self-administration in rats. Pharmacol Biochem Behav 2009, 92:676-682.
38. Tabor C.W., Tabor H., Polyamines Ann Rev Biochem 1984, 53:749-790.
39. Tahsili-Fahadan P., Firouz-Abadi N.Y., Khoshnoodi M.A., Langroudi R.M., Tahaei- Ghahremani M.H. Agmatine potentiates morphine-induced conditioned place preference in mice: modulation by alpha(2)-adrenoceptors. Neuropsychopharmacology 2006, 31:1722-1732.
40. Taksande B.G., Kotagale N.R., Patel M.R., Shelkar G.P., Ugale R.R., Chopde C.T. Agmatine an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. Eur J Pharmacol 2010, 637(1-3):89-101.
41. Taksande B.G., Kotagale N.R., Nakhate K.T., Mali P.D., Kokare D.M., Hirani K., et al. Agmatine in the hypothalamic paraventricular nucleus stimulates feeding in rats: involvement of neuropeptide Y. Br J Pharmacol 2011, 164:704-718.
42. Uzbay T., Yesilyurt O., Celik T., Isimer A. Effect of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res 2000, 107:153-159.
43. Wei X.L., Su R.B., Wu N., Lu X.Q., Zheng J.Q., Li J. Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats. Eur Neuropsychopharmacol 2007, 17:790-799.
44. Yesilyurt O., Uzbay I.T. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 2001, 25:98-103.
45. Zaniewska M., McCreary A.C., Sezer G., Przegalinski E., Filip M. Effects of agmatine on nicotine-evoked behavioral responses in rats. Pharmacol Rep 2008, 60:645-654.
46. Zhu M.Y., Wang W.P., Huang J., Regunathan S. Chronic treatment with glucocorticoids alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. J Neurochem 2007, 103(5):1811-1820.
47. Zislis G., Desai T.V., Prado M., Shah H.P., Bruijnzeel A.W. Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha 2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 2007, 53:958-966.